The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies.
Sign Up to like & getrecommendations! Published in 2020 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2020.115018
Abstract: The incorporation of mesenchymal-epithelial transition factor (c-Met) inhibitors with conventional chemotherapeutics may increase the anticancer efficacy of chemotherapeutic agents, but bears the risk of enhancing the adverse effects. To test the hypothesis, co-administration of the… read more here.
Keywords: capmatinib; cardiotoxicity; inhibitor capmatinib; dox ... See more keywords